Volume 99, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Reticulocyte-binding homologues (RH) are a ligand family that mediates merozoite invasion of erythrocytes in . Among the five members of this family identified so far, only reticulocyte–binding homologue-5 (PfRH5) has been found to be essential for parasite survival across strains that differ in virulence and route of host-cell invasion. Based on its essential role in invasion and early evidence of sequence conservation, PfRH5 has been prioritized for development as a vaccine candidate. However, little is known about the extent of genetic variability of RH5 in the field and the potential impact of such diversity on clinical outcomes or on vaccine evasion. Samples collected during a prospective cohort study of malaria incidence conducted in Kalifabougou, in southwestern Mali, were used to estimate genetic diversity, measure haplotype prevalence, and assess the within-host dynamics of PfRH5 variants over time and in relation to clinical malaria. A total of 10 nonsynonymous polymorphic sites were identified in the gene, resulting in 13 haplotypes encoding unique protein variants. Four of these variants have not been previously observed. reticulocyte–binding homologue-5 had low amino acid haplotype ( = 0.58) and nucleotide (π = 0.00061) diversity. By contrast to other leading blood-stage malaria vaccine candidate antigens, amino acid differences were not associated with changes in the risk of febrile malaria in consecutive infections. Conserved B- and T-cell epitopes were identified. These results support the prioritization of PfRH5 for possible inclusion in a broadly cross-protective vaccine.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

Loading full text...

Full text loading...



  1. Sutherland C, , 2007. A challenge for the development of malaria vaccines: polymorphic target antigens. PLoS Med 4: e116.
  2. Haywood M, Conway DJ, Weiss H, Metzger W, D’Alessandro U, Snounou G, Targett G, Greenwood B, , 1999. Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66. Trans R Soc Trop Med Hyg 93 (Suppl 1): 6568.
  3. Ouattara A, 2013. Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 207: 511519.
  4. Takala SL, Plowe CV, , 2009. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’. Parasite Immunol 31: 560573.
  5. Takala SL, 2009. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 1: 2ra5.
  6. Neafsey DE, 2015. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med 373: 20252037.
  7. Douglas AD, 2015. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in Aotus monkeys. Cell Host Microbe 17: 130139.
  8. Ord RL, Caldeira JC, Rodriguez M, Noe A, Chackerian B, Peabody DS, Gutierrez G, Lobo CA, , 2014. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malar J 13: 326.
  9. Campeotto I, Goldenzweig A, Davey J, Barfod L, Marshall JM, Silk SE, Wright KE, Draper SJ, Higgins MK, Fleishman SJ, , 2017. One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen. Proc Natl Acad Sci USA 114: 9981002.
  10. Hayton K, 2008. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 4: 4051.
  11. Crosnier C, 2011. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480: 534537.
  12. Douglas AD, Andrews L, Draper SJ, Bojang K, Milligan P, Gilbert SC, Imoukhuede EB, Hill AV, , 2011. Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis 203: 13371340.
  13. Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru M, Nguon C, Kwiatkowski DP, Wright GJ, Rayner JC, , 2013. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine 31: 373379.
  14. Manske M, 2012. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 487: 375379.
  15. Arevalo-Pinzon G, Curtidor H, Munoz M, Patarroyo MA, Bermudez A, Patarroyo ME, , 2012. A single amino acid change in the Plasmodium falciparum RH5 (PfRH5) human RBC binding sequence modifies its structure and determines species-specific binding activity. Vaccine 30: 637646.
  16. Tran TM, 2014. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis 209: 789798.
  17. Tran TM, 2013. An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis 57: 4047.
  18. Hall TA, , 1999. BioEdit: A User-Friendly Biological Sequence Alignment Editor and Analysis Program for Windows 95/98/NT. Oxford, United Kingdom: Oxford University Press, 95–98.
  19. Nei M, Gojobori T, , 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3: 418426.
  20. Tamura K, Dudley J, Nei M, Kumar S, , 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 15961599.
  21. Rozas J, , 2009. DNA sequence polymorphism analysis using DnaSP. Methods Mol Biol 537: 337350.
  22. Zhang J, Nielsen R, Yang Z, , 2005. Evaluation of an improved branch-site likelihood method for detecting positive selection at the molecular level. Mol Biol Evol 22: 24722479.
  23. Pond SL, Frost SD, Muse SV, , 2005. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676679.
  24. Hudson RR, , 2007. Estimating the recombination parameter of a finite population model without selection. Genet Res 89: 427432.
  25. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD, , 2006. GARD: a genetic algorithm for recombination detection. Bioinformatics 22: 30963098.
  26. Kelly JK, , 1997. A test of neutrality based on interlocus associations. Genetics 146: 11971206.
  27. Rozas J, Gullaud M, Blandin G, Aguade M, , 2001. DNA variation at the rp49 gene region of Drosophila simulans: evolutionary inferences from an unusual haplotype structure. Genetics 158: 11471155.
  28. Huelsenbeck JP, Jain S, Frost SW, Pond SL, , 2006. A Dirichlet process model for detecting positive selection in protein-coding DNA sequences. Proc Natl Acad Sci USA 103: 62636268.
  29. Falush D, Stephens M, Pritchard JK, , 2003. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164: 15671587.
  30. Lyke KE, 2011. Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens 77: 562571.
  31. Cao K, 2004. Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 63: 293325.
  32. Williams AR, 2012. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog 8: e1002991.
  33. Chiu CY, 2014. Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria. Front Microbiol 5: 314.
  34. Thera MA, 2011. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 10041013.
  35. Hodder AN, Crewther PE, Anders RF, , 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69: 32863294.
  36. Genton B, 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185: 820827.
  37. Obaro SK, Adegbola RA, Banya WA, Greenwood BM, , 1996. Carriage of pneumococci after pneumococcal vaccination. Lancet 348: 271272.
  38. Schouls LM, van der Ende A, van de Pol I, Schot C, Spanjaard L, Vauterin P, Wilderbeek D, Witteveen S, , 2005. Increase in genetic diversity of Haemophilus influenzae serotype b (Hib) strains after introduction of Hib vaccination in The Netherlands. J Clin Microbiol 43: 27412749.
  39. Baum J, Chen L, Healer J, Lopaticki S, Boyle M, Triglia T, Ehlgen F, Ralph SA, Beeson JG, Cowman AF, , 2009. Reticulocyte-binding protein homologue 5–an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol 39: 371380.
  40. Ouattara A, 2010. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J 9: 175.
  41. Sundararaman SA, 2016. Genomes of cryptic chimpanzee Plasmodium species reveal key evolutionary events leading to human malaria. Nat Commun 7: 11078.
  42. Wright KE, 2014. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 515: 427430.
  43. Barry AE, Schultz L, Senn N, Nale J, Kiniboro B, Siba PM, Mueller I, Reeder JC, , 2013. High levels of genetic diversity of Plasmodium falciparum populations in Papua New Guinea despite variable infection prevalence. Am J Trop Med Hyg 88: 718725.
  44. Osier FH, 2010. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect Immun 78: 46254633.
  45. Ntege EH, Arisue N, Ito D, Hasegawa T, Palacpac NMQ, Egwang TG, Horii T, Takashima E, Tsuboi T, , 2016. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Vaccine 34: 56125622.
  46. Galaway F, Drought LG, Fala M, Cross N, Kemp AC, Rayner JC, Wright GJ, , 2017. P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5. Nat Commun 8: 14333.
  47. Douglas AD, 2011. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2: 601.
  48. Heppner DG, Jr. 2005. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23: 22432250.
  49. Fluck C, Schopflin S, Smith T, Genton B, Alpers MP, Beck HP, Felger I, , 2007. Effect of the malaria vaccine combination B on merozoite surface antigen 2 diversity. Infect Genet Evol 7: 4451.
  50. Takala SL, 2007. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med 4: e93.
  51. Gandhi K, Thera MA, Coulibaly D, Traore K, Guindo AB, Ouattara A, Takala-Harrison S, Berry AA, Doumbo OK, Plowe CV, , 2014. Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications. PLoS One 9: e101783.

Data & Media loading...

  • Received : 20 Sep 2017
  • Accepted : 27 Mar 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error